Loading
Life sciences · Interventional Study
ClinicalTrials.gov · October 6, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Interventional Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06370988). This is a study registration, not published results. Lead sponsor: Centre for Addiction and Mental Health. Recruitment status: RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 124 participants (ESTIMATED). Conditions: Bipolar Depression, Bipolar Disorder, Treatment- Resistant Bipolar Disorder, Type 2 Bipolar Disorder. Interventions: DEVICE: iTBS Stimulation; DEVICE: Sham iTBS Stimulation. Primary outcome measures: Change on the 17-item Hamilton Rating Scale for Depression (HRSD-17) , From enrollment to 6 weeks post-treatment. Brief summary: The purpose of this trial is to determine if intermittent theta-burst stimulation (iTBS) can reduce the symptoms of depression in treatment-resistant bipolar disorder. To do this, some of the participants in this study will receive treatment with active iTBS stimulation, while others will receive sham iTBS stimulation. Participants will come for 30 days of either active iTBS or sham iTBS, with a 6-week follow-up period. Symptoms of depression (for determining treatment efficacy) and mania (for determining treatment safety) will be assessed using the 17-item Hamilton Rating Scale for Depression (HRSD-17) and the Young Mania Rating Scale (YMRS) every five treatments during the treatment course, and at 1 week and 6 week after treatment completion.